Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Baxter
Citi
Healthtrust
UBS
Chubb

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 5,972,712

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,972,712
Title: Heparin-independent, high sensitivity platelet function evaluation technique
Abstract:An method for performing activated clotting time tests, including a method for evaluating platelet functionality of a blood sample. The method includes the steps of combining a heparin-inactivating agent, an anticoagulant agent, a sufficient amount of clotting reagent to achieve clotting, a platelet activating agent, and the sample of blood to be tested to form a test mixture. The platelet activating agent is a reagent other than the clotting reagent. The platelets of the sample are activated by agitating the test mixture, and the activated clotting time test is terminated upon detecting a predetermined change in a property of the test mixture. The activated clotting time of the sample of blood is calculated based on the elapsed time. The activated clotting time test may be performed using a plunger sensor apparatus which comprises a plurality of test cells. In this method, each of the cells of the apparatus includes a heparin-inactivating agent, an anticoagulant agent, and a sufficient amount of a clotting reagent to achieve clotting. At least one of the test cells further includes a platelet activating agent, which is a reagent other than the clotting reagent. The clotting time is determined for each of the aliquot portions, and the relative clotting times of the aliquot portions in the cells are determinative of the platelet functionality of the sample.
Inventor(s): Baugh; Robert F. (Parker, CO), Lane; Carole G. (Greenwood Village, CO), Wilson; Adrian C. (Denver, CO)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Application Number:09/249,349
Patent Claims:see list of patent claims

Details for Patent 5,972,712

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22 ➤ Sign Up Medtronic, Inc. (Minneapolis, MN) 2017-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
UBS
Moodys
Daiichi Sankyo
Express Scripts
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.